Tag: file

Singapore, July 01, 2025 (GLOBE NEWSWIRE) -- Origin Investment Corp I (the “Company”), a blank check company, today announced the pricing of its initial public offering (“IPO”) of 6,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. The units are expected to begin trading on the Nasdaq Global Market (“Nasdaq”) on July 2, 2025 under the ticker symbol “ORIQU”. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as described in the prospectus. Only whole warrants are exercisable. The warrants will become exercisable 30 days after the completion of the Company’s initial business combination, and will expire five years after the completion of the Company’s initial business combination or earlier upon redemption or the Company’s liquidation. The offering is expected to close on July 3, 2025, subject to satisfaction of customary closing conditions. Once the securities comprising the units begin separate trading, the Class A ordinary shares and the warrants are expected to be traded on Nasdaq under the symbols “ORIQ” and “ORIQW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. In addition, the Company has granted the underwriters a 45-day option to purchase up to 900,000 additional units at the IPO price to cover over-allotments, if any.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030. Is it a fair deal?

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the “Warrants”). The combined public Offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00 (the “Offering”). The Preferred Stock is convertible into the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a conversion price of $2.50 per share. The closing of the Offering is expected to occur on or about July 2, 2025, subject to the satisfaction of customary closing conditions.

FREMONT, Calif, July 01, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced that it has entered into definitive agreements for the issuance and sale of 1,626,019 shares of its common stock, Series A-3 warrants to purchase up to an aggregate of 1,626,019 shares of common stock and short-term Series A-4 warrants to purchase up to an aggregate of 3,252,038 shares of common stock, at a purchase price of $0.615 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules.

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1

Combined Company Expected to be Listed on NASDAQ Global Market

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.